The Board of Directors of Opto Circuits (India) Ltd. (OCI), India’s leading manufacturer of medical diagnostics and interventional products, today approved and adopted the company’s Unaudited Financial Results for the third quarter and first nine months ended December 31, 2007. On a consolidated basis, the company posted a 103 per cent growth in sales that stand at Rs. 127.32 crore for the third quarter ended 31st December 2007 as compared to Rs. 62.80 crore for the corresponding period last year. The Net Profit for the quarter stood at Rs. 35.74 crore, as against Rs. 20.01 crore for the same period in the previous year, a 79% rise.

For the nine months ended December 31st 2007, OCI posted consolidated sales of Rs. 347.60 crore as against Rs. 167.37 crore of the corresponding period and a net profit of Rs.97.63 crore as against 49.02 crore for the same period in the previous year with an increase of 108 per cent in sales and 99 per cent on profits.

Speaking after the announcement of results, Vinod Ramnani, Chairman & Managing Director, said, “We are looking at new markets for exploring the possibility of increasing our market share. We are confident of making a significant imprint in the global market through in-organic growth and wider market spread.”

In the last quarter, the company has received the Section 510K US FDA approval on two of its new generation range of Pulse Oximeters viz., M30 and M34 which has the largest market in United States. The Company has obtained accreditation of ISO 14001:2004 for Environmental Management System and also OHSAS 18001:2007 for occupational Health and Safety Management System.

Sourced From: Adfactors Public Relations Pvt Ltd

Tags: calls, daytrading, free calls, intraday, tips

Similar Posts:

• Opto Circuits Q4 net up 62% at Rs 55 cr
• Alembic Q3FY08 sales at Rs 265cr up 39%
• Bartronics posts 217.71% rise in net profit
• Net4’s PAT surges 44.4% in Q1FY09
• IndusInd Bank’s net profit of Rs 25.04cr for Q3FY08